Skip to main content
SpringerLink
Log in

Prediction of Efficacy and Side Effects of Chemotherapy in Colorectal Cancer

  • Chapter
Targeted Therapies in Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 176))

Abstract

Treatment of gastrointestinal cancers has significantly advanced over the last several years with the introduction of effective chemotherapeutic and targeted drugs. Providing individual treatment with low toxicity but maximum benefit is still an unsolved problem. Inter-individual variation of drug toxicity and efficacy is mainly determined by genetic polymorphisms. The genetic approach of pharmacogenetics and pharmacogenomics is developing as a valuable tool to design tailored therapy. This review focuses on clinically significant polymorphisms in genes involved in metabolism of chemotherapy used in gastrointestinal cancer: fluoropyrimidines, irinotecan, and platinum. In addition, the first results of pharmacogenetics in targeted therapy including cetuximab and bevacizumab are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 60:6921–6926

    PubMed  CAS  Google Scholar 

  • Ban N, Takahashi Y, Takayama T, Kura T, Katahira T, Sakamaki S, Niitsu Y (1996) Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 56:3577–3582

    PubMed  CAS  Google Scholar 

  • Danenberg PV (1977) Thymidylate synthetase—a target enzyme in cancer chemotherapy. Biochim Biophys Acta 473:73–92

    PubMed  CAS  Google Scholar 

  • Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47–51

    PubMed  CAS  Google Scholar 

  • Etienne MC, Chazal M, Laurent-Puig P, Magne N, Rosty C, Formento JL, Francoual M, Formento P, Renee N, Chamorey E, Bourgeon A, Seitz JF, Delpero JR, Letoublon C, Pezet D, Milano G (2002) Prognostic value of tumoral thymidylate synthase and p53 in metastatic colorectal cancer patients receiving fluorouracil-based chemotherapy: phenotypic and genotypic analyses. J Clin Oncol 20:2832–2843

    Article  PubMed  CAS  Google Scholar 

  • Goto S, Iida T, Cho S, Oka M, Kohno S, Kondo T (1999) Overexpression of glutathione S-transferase pi enhances the adduct formation of cisplatin with glutathione in human cancer cells. Free Radic Res 31:549–558

    Article  PubMed  CAS  Google Scholar 

  • Grothey A, McLeod HL, Green EM, Sargent DJ, Fuchs C, Ramanathan RK, Williamson SK, Findlay BP, Goldberg RM (2005) Glutathione S-transferase P1 I105 V (GSTP1 I105 V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. Proc Am Soc Clin Oncol Abstr 509

    Google Scholar 

  • Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB (1987) Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47:2203–2206

    PubMed  CAS  Google Scholar 

  • Horie N, Aiba H, Oguro K, Hojo H, Takeishi K (1995) Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 20:191–197

    Article  PubMed  CAS  Google Scholar 

  • Iacopetta B, Grieu F, Joseph D, Elsaleh H (2001) A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 85:827–830

    Article  PubMed  CAS  Google Scholar 

  • Ichikawa W, Nihei Z, Shirota Y, Suto K, Hirayama R (2003) Polymorphism of orotate phosphoribosyl transferase (OPRT) gene and tymidylate synthase tandem repeat (TSTR) predict adverse events (AE) in colorectal cancer (CRC) patients treated with 5-fluorouracil (FU) plus leucovorin (LV). Proc Am Soc Clin Oncol Abstr 1063

    Google Scholar 

  • Innocenti F, Iyer L, Ratain MJ (2001) Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos 29:596–600

    PubMed  CAS  Google Scholar 

  • Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katayuma T, Maekawa Y (2002) Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vivo chemosensitivity to 5-FU. Int J Clin Oncol 7:335–342

    Article  PubMed  CAS  Google Scholar 

  • Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847–854

    PubMed  CAS  Google Scholar 

  • Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999) Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5:2006–2011

    PubMed  CAS  Google Scholar 

  • Kaneda S, Takeishi K, Ayusawa D, Shimizu K, Seno T, Altman S (1987) Role in translation of a triple tandemly repeated sequence in the 5′-untranslated region of human thymidylate synthase mRNA. Nucleic Acids Res 15:1259–1270

    Article  PubMed  CAS  Google Scholar 

  • Kawakami K, Salonga D, Park JM, Danenberg KD, Uetake H, Brabender J, Omura K, Watanabe G, Danenberg PV (2001) Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res 7:4096–4101

    PubMed  CAS  Google Scholar 

  • Kundu NG, Heidelberger C (1974) Cyclopenta(f)iso quinoline derivatives designed to bind specifically to native deoxyribonucleic acid. 3. Interaction of 6-carbamoylmethyl-8-methyl-7H-cyclopenta(f)iso quinoline-3 (2H)-one with deoxyribonucleic acids and polydeoxyribonucleotides. Biochem Biophys Res Commun 60:561–568

    Article  PubMed  CAS  Google Scholar 

  • Leichman CG, Lenz HJ, Leichman L, Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M, Danenberg PV (1997) Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 15:3223–3229

    PubMed  CAS  Google Scholar 

  • Lu B, Gil B, Zhang W, Stoehlmacher J, Zahedy S, Mallik N, Lenz HJ (2002) Thymidylate synthase polymorphism predicts pelvic recurrence in rectal cancer patients treated with combined modalities. Proc Am Soc Clin Oncol 21:Abstr 2237

    Google Scholar 

  • Luo HR, Lu XM, Yao YG, Horie N, Takeishi K, Jorde LB, Zhang YP (2002) Length polymorphism of thymidylate synthase regulatory region in Chinese populations and evolution of the novel alleles. Biochem Genet 40:41–51

    Article  PubMed  CAS  Google Scholar 

  • Mandola M, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD (2003) A novel single nucleotide polymorphism within the 5′ tandem repeat polymorphism of the thymidylate synthase gene abolishes USF-1 binding and alters transcriptional activity. Cancer Res 63:2898–2904

    PubMed  CAS  Google Scholar 

  • Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RD (2004) A 6 bp/1494 deletion polymorphism in the 3′-UTR of human thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319–327

    Article  PubMed  CAS  Google Scholar 

  • Marcuello E, Altes A, Menoyo A, Del Rio E, Gomez-Pardo M, Baiget M (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 91:478–482

    Google Scholar 

  • Marsh S, Collie-Duguid ES, Li T, Liu X, McLeod HL (1999) Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58:310–312

    Article  PubMed  CAS  Google Scholar 

  • McArdle CS, Hole D (1991) Impact of variability among surgeons on postoperative morbidity and mortality and ultimate survival. BMJ 302:1501–1505

    Article  PubMed  CAS  Google Scholar 

  • McLeod HL, Collie-Duguid ES, Vreken P, Johnson MR, Wei X, Sapone A, Diasio RB, Fernandez-Salguero P, van Kuilenberg AB, van Gennip AH, Gonzalez FJ (1998) Nomenclature for human DPYD alleles. Pharmacogenetics 8:455–459

    PubMed  CAS  Google Scholar 

  • McLeod H, Sargent D, Marsh S, Fuchs C, Ramanathan R, Williamson S, Findlay B, Thibodeau S, Petersen G, Goldberg R (2003) Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5-FU)/CPT-11, 5-FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): results from an intergroup trial. Proc Am Soc Clin Oncol Abstr 1013

    Google Scholar 

  • Park DJ, Stoehlmacher J, Zhang W, Tsao-Wei DD, Groshen S, Lenz HJ (2001) A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res 61:8654–8658

    PubMed  CAS  Google Scholar 

  • Pullarkat ST, Stoehlmacher J, Ghaderi V, Xiong YP, Ingles SA, Sherrod A, Warren R, Tsao-Wei D, Groshen S, Lenz HJ (2001) Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65–70

    PubMed  CAS  Google Scholar 

  • Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E (2004) Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 10:5151–5159

    Article  PubMed  CAS  Google Scholar 

  • Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19:4298–4304

    PubMed  CAS  Google Scholar 

  • Srivastava S, Singhal S, Hu X, Awasthi Y, Zimniak P, Singh S (1999) Differential catalytic efficiency of allelic variants of human glutathione S-transferase Pi in catalyzing the glutathione conjugation of thiotepa. Arch Biochem Biophys 366:89–94

    Article  PubMed  CAS  Google Scholar 

  • Stoehlmacher J, Park DJ, Zhang W, Groshen S, Tsao-Wei DD, Yu MC, Lenz HJ (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942

    PubMed  CAS  Google Scholar 

  • Stoehlmacher J, Park DJ, Zhang W, Tsao-Wei D, Groshen S, Zahedy S, Lenz HJ (2004) A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-fluorouracil/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344–354

    PubMed  CAS  Google Scholar 

  • Tsuji T, Hidaka S, Sawai T, Nakagoe T, Yano H, Haseba M, Komatsu H, Shindou H, Fukuoka H, Yoshinaga M, Shibasaki S, Nanashima A, Yamaguchi H, Yasutake T, Tagawa Y (2003) Polymorphism in the thymidylate synthase promoter enhancer region is not an efficacious marker for tumor sensitivity to 5-fluorouracil-based oral adjuvant chemotherapy in colorectal cancer. Clin Cancer Res 9:3700–3704

    PubMed  CAS  Google Scholar 

  • van Kuilenburg AB, Vreken P, Beex LV, Meinsma R, Van Lenthe H, De Abreu RA, van Gennip AH (1997) Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer 33:2258–2264

    Article  PubMed  Google Scholar 

  • van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, Baas F, Richel DJ, van Gennip AH (2001) Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res 7:1149–1153

    PubMed  Google Scholar 

  • Villafranca E, Okruzhnov Y, Dominguez MA, Garcia-Foncillas J, Azinovic I, Martinez E, Illarramendi JJ, Arias F, Martinez Monge R, Salgado E, Angeletti S, Brugarolas A (2001) Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779–1786

    PubMed  CAS  Google Scholar 

  • Zhang W, Gordon M, Press OA, Rhodes K, Vallbohmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ (2006) Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 16:475–483

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine I Haematology and Medical Oncology, University Hospital Carl Gustav Carus Dresden, Fetscherstr. 74, 01307, Dresden, Germany

    Jan Stoehlmacher MD

Authors
  1. Jan Stoehlmacher MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pathologie, Charité Humboldt-Universität zu Berlin, Schumanstr. 20-21, 10117, Berlin, Germany

    Manfred Dietel

Rights and permissions

Reprints and permissions

Copyright information

© 2007 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stoehlmacher, J. (2007). Prediction of Efficacy and Side Effects of Chemotherapy in Colorectal Cancer. In: Dietel, M. (eds) Targeted Therapies in Cancer. Recent Results in Cancer Research, vol 176. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-46091-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-46091-6_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-46090-9

  • Online ISBN: 978-3-540-46091-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation